Search by Drug Name or NDC
NDC 25021-0245-01 Docetaxel 20 mg/mL Details
Docetaxel 20 mg/mL
Docetaxel is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Sagent Pharmaceuticals. The primary component is DOCETAXEL ANHYDROUS.
MedlinePlus Drug Summary
Docetaxel injection is used alone or in combination with other medications to treat certain types of breast, lung, prostate, stomach, and head and neck cancers. Docetaxel injection is in a class of medications called taxanes. It works by stopping the growth and spread of cancer cells.
Related Packages: 25021-0245-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Docetaxel Injection
Product Information
| NDC | 25021-0245 |
|---|---|
| Product ID | 25021-245_9ebbe3c6-4c2b-4391-8352-fa96b2bc2f4c |
| Associated GPIs | 21500005001310 21500005001315 |
| GCN Sequence Number | 066750 |
| GCN Sequence Number Description | docetaxel VIAL 20MG/ML(1) INTRAVEN |
| HIC3 | V1F |
| HIC3 Description | ANTINEOPLASTICS,MISCELLANEOUS |
| GCN | 28663 |
| HICL Sequence Number | 010280 |
| HICL Sequence Number Description | DOCETAXEL |
| Brand/Generic | Generic |
| Proprietary Name | Docetaxel |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Docetaxel Anhydrous |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 20 |
| Active Ingredient Units | mg/mL |
| Substance Name | DOCETAXEL ANHYDROUS |
| Labeler Name | Sagent Pharmaceuticals |
| Pharmaceutical Class | Microtubule Inhibition [PE], Microtubule Inhibitor [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA207252 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 25021-0245-01 (25021024501)
| NDC Package Code | 25021-245-01 |
|---|---|
| Billing NDC | 25021024501 |
| Package | 1 VIAL in 1 CARTON (25021-245-01) / 1 mL in 1 VIAL |
| Marketing Start Date | 2017-09-15 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |